• Administration: Elelyso is administered intravenously (IV) by a healthcare professional. The infusion takes about 1 hour, and patients are typically monitored during and after the infusion for any signs of adverse reactions.
  
  Before administration: The healthcare provider will carefully calculate the appropriate dosage based on the patient’s body weight.
  
  Monitoring: During the infusion, patients will be monitored for signs of allergic reactions or other side effects, such as fever, chills, or rash.
  
  
• Missed Dose: If a dose is missed, the patient should contact their healthcare provider immediately. The infusion will usually be rescheduled as soon as possible, and the provider will determine the best course of action based on the patient’s condition.
  
  

Elelyso works by providing a recombinant version of the glucocerebrosidase enzyme, which is missing or deficient in people with Gaucher disease. The enzyme is responsible for breaking down glucocerebroside, a fatty substance that accumulates in the body when the enzyme is not functioning properly.

• Replaces Deficient Enzyme: Elelyso helps reduce the accumulation of glucocerebroside in cells by acting as a replacement for the deficient or absent enzyme. This enzyme replacement therapy can help reduce the size of enlarged organs like the spleen and liver, improve blood cell counts, and alleviate bone pain and fractures associated with Gaucher disease.
  
  
• Reduces Disease Symptoms: By increasing the breakdown of glucocerebroside, Elelyso helps to restore the balance of lipids in the body, which leads to symptom improvement such as reduced organ size, fewer blood-related issues, and improved overall health.
  
  

Elelyso is designed to mimic the natural glucocerebrosidase enzyme, so it can be recognized and processed by the body’s cells, helping to manage the underlying cause of Gaucher disease.

While Elelyso is generally well-tolerated, like all medications, it may cause side effects in some people. Common side effects of Elelyso may include:

• Infusion-related reactions: These can include symptoms like:
  
  
  • Fever
    
    
  • Chills
    
    
  • Rash
    
    
  • Fatigue
    
    
  • Headache
    
    
  • Nausea
    
    
• These reactions are usually mild and go away after the infusion is completed.
  
  
• Allergic Reactions: Some individuals may experience more serious allergic reactions, such as shortness of breath, swelling, or itching. If any signs of a severe allergic reaction occur, it’s important to seek medical attention immediately.
  
  
• Joint pain or bone pain: Although Elelyso is designed to alleviate bone pain in Gaucher disease, some patients may still experience pain in their bones or joints.
  
  
• Other potential side effects: These may include symptoms like dizziness, abdominal pain, and gastrointestinal issues, though these are less common.
  
  

• Allergic Reactions: As with any intravenous medication, there is a risk of an allergic reaction. Patients should be monitored for any signs of hypersensitivity during the infusion. If any severe allergic reactions occur, the infusion should be stopped immediately, and appropriate medical treatment should be provided.
  
  
• Immune Response: Some individuals may develop antibodies against Elelyso. The development of these antibodies could reduce the effectiveness of the therapy. Therefore, it is important for patients to regularly follow up with their healthcare provider to monitor for any signs of immune response.
  
  
• Pregnancy and Breastfeeding: There are limited studies regarding the use of Elelyso during pregnancy and breastfeeding. Pregnant women and nursing mothers should discuss the potential risks and benefits with their healthcare provider before starting treatment with Elelyso.
  
  

Pre-treatment Screening: Before starting Elelyso, a healthcare provider will typically screen for any history of allergies or immune-related conditions to ensure the treatment is safe for the individual.

•  There are no significant known drug interactions with Elelyso; however, patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to ensure there are no potential interactions.
  
  
  • Immune Response: In some cases, patients may develop an immune response to Elelyso, which could affect the treatment’s effectiveness. This is particularly important if a patient is also receiving other enzyme replacement therapies or immunosuppressive medications.
    
    

Vaccinations: It is advised to consult a healthcare provider about any necessary vaccinations before starting Elelyso, as certain live vaccines might be contraindicated while on enzyme replacement therapy.

• Initial Dose: The starting dose for adults and children over 2 years of age is 60 units per kilogram of body weight, administered via IV infusion every 2 weeks.
  
  
• Maintenance Dose: After the initial treatment period, the frequency of infusions may be adjusted based on the patient’s clinical response, with many patients transitioning to infusions every 3-4 weeks once their condition is stabilized.
  
  

Dose Adjustment: Your healthcare provider will monitor your response to Elelyso and may adjust your dose or infusion schedule accordingly.

Elelyso is a prescription-only medication, and it must be administered under the supervision of a healthcare professional. This is because it is given via an intravenous (IV) infusion, and the patient’s response to the therapy needs to be carefully monitored for side effects and effectiveness.

Patients will need to have regular check-ups with their healthcare provider to evaluate the effectiveness of Elelyso and adjust the treatment plan as necessary.

1. What is Elelyso?
   Elelyso is a prescription medicine used for enzyme replacement therapy in people with Type 1 Gaucher disease.

2. What condition does Elelyso treat?
   It treats Type 1 Gaucher disease, a rare inherited disorder where the body does not produce enough of the enzyme glucocerebrosidase.

3. How does Elelyso work?
   Elelyso replaces the missing enzyme, helping the body break down fatty substances that build up in certain organs.

4. Who can use Elelyso?
   It is approved for adults and children 4 years and older with Type 1 Gaucher disease.

5. How is Elelyso given?
   It is administered by intravenous (IV) infusion every two weeks.

6. How long does an Elelyso infusion take?
   Each infusion usually lasts about 1–2 hours, depending on the dose and patient tolerance.

7. What are the common side effects of Elelyso?
   Side effects may include headache, joint pain, nausea, stomach pain, itching, rash, and infusion-related reactions.

8. Are infusion reactions common with Elelyso?
   Yes, some patients may experience fever, flushing, rash, or breathing problems during or after infusion.

9. Can Elelyso be used during pregnancy?
   It should only be used if clearly needed. Patients should consult their doctor before use.

10. Can Elelyso be used while breastfeeding?
    It is unknown if Elelyso passes into breast milk. A doctor’s guidance is necessary.

11. How is the dose of Elelyso determined?
    The dose is based on the patient’s weight and medical condition.

12. Does Elelyso cure Gaucher disease?
    No, it does not cure the disease but helps manage symptoms and prevent complications.

13. What should I do if I miss a dose of Elelyso?
    Contact your doctor or infusion center to reschedule the infusion as soon as possible.

14. Are there any drug interactions with Elelyso?
    Currently, no major drug interactions are known, but always inform your doctor of all medications and supplements.

15. Is Elelyso the only enzyme replacement therapy for Gaucher disease?
    No, other treatments include imiglucerase (Cerezyme) and velaglucerase alfa (VPRIV).

16. Can children receive Elelyso?
    Yes, it is approved for children 4 years and older.

17. What should I tell my doctor before starting Elelyso?
    Inform them about allergies, medical history, pregnancy, breastfeeding, and all medications you are taking.

18. How is Elelyso stored before infusion?
    It is supplied as a powder and must be refrigerated until prepared by a healthcare professional.

19. Who manufactures Elelyso?
    Elelyso is manufactured by Pfizer, in partnership with Protalix BioTherapeutics.

20. Is financial assistance available for Elelyso treatment?
    Yes, Pfizer and other patient assistance programs may help cover costs for eligible patients.